Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

Abstract: Proteo-microparticles such as proteoliposomes comprising a microparticle (e.g., a liposome) and platelet membrane proteins, wherein the proteo-microparticles are capable of binding to monocytes, neutrophils, or other circulating blood cells capable of migrating to an injured site. Also provided herein are uses of the proteoliposomes for delivering a therapeutic agent via monocytes to an injured site.

Abstract: Aspects of the invention can include a teleconferencing system having a system housing, a speaker enclosure configured within the system housing, a speaker mounted to the speaker enclosure, and one or more damping cushions coupling the speaker enclosure to the system housing. The one or more damping cushions can suspend the speaker enclosure within the system housing such that the speaker enclosure is separated and mechanically isolated from the system housing by at least a minimum distance (e.g., 2 mm). In some cases, the one or more damping cushions provide the only structural coupling between the speaker enclosure and the system housing. The one or more damping cushions can be configured to dampen mechanical energy generated by the speaker thereby preventing at least a portion of the mechanical energy form coupling to the system housing via the one or more damping cushions.

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.

Abstract: Aspects of the invention can include a teleconferencing system having a system housing, a speaker enclosure configured within the system housing, a speaker mounted to the speaker enclosure, and one or more damping cushions coupling the speaker enclosure to the system housing. The one or more damping cushions can suspend the speaker enclosure within the system housing such that the speaker enclosure is separated and mechanically isolated from the system housing by at least a minimum distance (e.g., 2 mm). In some cases, the one or more damping cushions provide the only structural coupling between the speaker enclosure and the system housing. The one or more damping cushions can be configured to dampen mechanical energy generated by the speaker thereby preventing at least a portion of the mechanical energy form coupling to the system housing via the one or more damping cushions.

Abstract: Proteo-microparticles such as proteoliposomes comprising a microparticle (e.g., a liposome) and platelet membrane proteins, wherein the proteo-microparticles are capable of binding to monocytes, neutrophils, or other circulating blood cells capable of migrating to an injured site. Also provided herein are uses of the proteoliposomes for delivering a therapeutic agent via monocytes to an injured site.

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemic disease is also provided.

Abstract: A webcam includes an external housing; a lens system disposed in the external housing; and a lens cap disposed in the external housing and configured to at least partially surround the lens system, wherein a gap is formed between the lens system and the lens cap.